- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07672392
The Effect of a Post-operative Exercise Programme Versus Standard Care on Physical Fitness of Patients With Breast Cancer Undergoing Deep Inferior Epigastric Perforator (DIEP) Flap Reconstruction Surgery (EXERCISE DIEP)
All patients undergoing mastectomy for breast cancer should be offered the option of reconstructive surgery. The Deep Inferior Epigastric Perforator Flap or DIEP reconstruction as it is commonly referred to, is becoming the favoured reconstruction by both patients and surgeons as it gives a great cosmetic outcome as well as being a good option for patients who may have to undergo radiotherapy treatment after their surgery.
Exercise has been demonstrated in previous research to improve tolerance of treatment (particularly chemotherapy), post operative fatigue and the overall quality of life in patients undergoing cancer treatment. Furthermore, it has shown to improve survival in patients who are being treated for breast cancer. The investigators are undertaking this study to investigate whether a structured exercise programme will improve patients fitness after surgery and ultimately improve their recovery after their reconstructive surgery. To do this, half of the people taking part will be undertaking a structured exercise programme and the other half will not and will be assessing which group recover better after their surgery. Currently, no breast reconstruction patients in Ireland are receiving a formal "exercise prescription" after their surgery so will be looking to see if this helps people recover better before it is made standard care for every breast patient in Ireland.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
To evaluate the impact of a structured, post-operative exercise programme on patient-reported and functional outcomes following DIEP flap breast reconstruction.
Secondary Objectives:
- To examine the effects of the exercise programme on upper and lower limb strength, body composition (BMI, fat and muscle mass, bone density), and functional recovery.
- To evaluate the influence of exercise on post-operative complication rates, length of hospital stay and time to return to daily activities.
- To explore changes in psychological health and body image perception using validated questionnaires.
- To assess adherence, feasibility, and safety of the structured exercise programme within a breast reconstruction population.
- To perform an exploratory health-economic analysis comparing the costs and potential healthcare savings associated with the intervention versus standard care.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Aisling Hegarty, PhD
- Phone Number: 018093000
- Email: Aislinghegarty@rcsi.ie
Study Contact Backup
- Name: Arnold Hill, MB, BCh, BAO, MCh, FRCSI
- Phone Number: +35318093000
- Email: adkhill@rcsi.com
Study Locations
-
-
Dublin
-
Beaumont, Dublin, Ireland, D09V2N0
- Recruiting
- Beaumont RCSI Cancer Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women aged 18 years and older
Candidates who have already been selected to undergo mastectomy and reconstruction by the breast MDT for the following indications:
- Genetic mutation carriers undergoing risk-reducing mastectomy.
- Ductal carcinoma in situ (DCIS) requiring mastectomy.
- Early invasive breast cancer requiring mastectomy.
- The tumour must not have skin involvement and no evidence of invasive disease within 1cm of skin, nipple or pectoralis major muscle (as proven on MRI).
- Candidates for breast reconstruction with DIEP.
- Fluent in English
- Fit for general anaesthetic Signed informed consent form
Exclusion Criteria:
- Advanced breast cancer with skin involvement.
- Undergoing bilateral DIEP reconstruction or other forms of breast reconstruction (e.g., TRAM, implant-based, LD flap).
- Pregnancy
- Lactation Patients with insufficient English to sign an informed consent (i.e. interpreter required).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
Structured individualised 12-week post operative exercise programme based on ACSM oncology guidelines, incorporating aerobic, resistance and flexibility training delivered in person or via zoom.
|
Structured individualised 12-week post operative exercise programme based on ACSM oncology guidelines, incorporating aerobic, resistance and flexibility training delivered in person or via zoom.
|
|
No Intervention: Control
standard post-operative care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiorespiratory Fitness
Time Frame: Measured at baseline (recruitment), 6 months postoperatively and at 1 year postoperatively
|
Cardiorespiratory fitness measured using the 6-Minute Walk Test (6MWT).
Outcome reported as change in distance walked (metres) from baseline to 6 months post-operatively.
Greater distance indicates improved cardiorespiratory fitness.
|
Measured at baseline (recruitment), 6 months postoperatively and at 1 year postoperatively
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hand Grip Strength
Time Frame: 6 months and 12 months post operatively
|
Measured using a hand dynamometer and reported in kilograms.
|
6 months and 12 months post operatively
|
|
Body Mass Index
Time Frame: At six months and 12 months postoperatively
|
Body mass index (BMI) calculated from measured weight and height and reported in kilograms per square meter (kg/m²).
|
At six months and 12 months postoperatively
|
|
EQ5D5L Health Related Quality of Life
Time Frame: At 6 months and 12 months post operatively
|
Quality of Life and Psychosocial Health: Assessed using the BREAST-Q (psychosocial and sexual well-being domains)
|
At 6 months and 12 months post operatively
|
|
Percentage Body Fat
Time Frame: At 6 months and 12 months postoperatively
|
Percentage body fat measured using bioelectrical impedance analysis with a Tanita device and reported as percentage body fat (%).
|
At 6 months and 12 months postoperatively
|
|
Muscle Mass
Time Frame: At 6 months and 12 months postoperatively
|
Muscle mass measured using bioelectrical impedance analysis with a Tanita device and reported in kilograms (kg).
|
At 6 months and 12 months postoperatively
|
|
Bone Mass
Time Frame: At 6 months and 12 months postoperatively
|
Bone mass measured using bioelectrical impedance analysis with a Tanita device and reported in kilograms (kg).
|
At 6 months and 12 months postoperatively
|
|
Lower Limb Strength
Time Frame: Measured at 6 months and 1 year postoperatively.
|
Measured using the 30 second Sit to Stand Test
|
Measured at 6 months and 1 year postoperatively.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 23-41
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
University of California, IrvineNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedBreast Cancer | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | HER2-negative Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Joseph Baar, MD, PhDCompletedBreast Cancer | Stage I Breast Cancer | Inflammatory Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast CancerUnited States
-
Case Comprehensive Cancer CenterNational Institute on Minority Health and Health Disparities (NIMHD)CompletedCancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedInflammatory Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
University of Maryland, BaltimoreSyndax PharmaceuticalsTerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Triple-negative Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast CancerUnited States
Clinical Trials on Structured individualised 12-week post operative exercise programme
-
University of GlasgowSuspendedExerciseUnited Kingdom
-
University of PadovaCompleted
-
Erzincan Binali Yildirim UniversitesiCompletedShoulder Dysfunction | Cardiac Implantable Electronic Device (CIED)Turkey (Türkiye)
-
Fundacin Biomedica Galicia SurRecruitingBariatric Patients | Obesity/Therapy | Bariatric Surgery and Physical Activity | Bariatric Surgery ComplicationsSpain
-
The Hong Kong Polytechnic UniversityCompletedTotal Knee ArthroplastyHong Kong
-
Royal Free Hospital NHS Foundation TrustUniversity College, LondonRecruitingKidney Diseases | Urinary Tract Infections | Kidney Transplant Failure and RejectionUnited Kingdom
-
University of NottinghamUniversity Hospitals of Derby and Burton NHS Foundation TrustCompletedColorectal Neoplasms | Colorectal CancerUnited Kingdom
-
Hacettepe UniversityNot yet recruitingNon-Small Cell Lung CancerTurkey (Türkiye)